{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:57:14Z","timestamp":1791284234194,"version":"4.1.0"},"reference-count":12,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablets (AuvelityTM) became the second medication to be approved by the FDA for the treatment of agitation in Alzheimer\u2019s disease dementia after brexpiprazole. It also became the first non-antipsychotic medication to be approved for this specific indication. In this Editorial, the available data regarding the efficacy and adverse effects of this medication in the treatment of agitation in Alzheimer\u2019s disease dementia are reviewed.<\/jats:p>","DOI":"10.7573\/dic.2026-6-4","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:48:13Z","timestamp":1791283693000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["A review of dextromethorphan and bupropion (Auvelity\u2122) for the treatment of agitation in Alzheimer\u2019s disease"],"prefix":"10.7573","author":[{"given":"Rajesh R","family":"Tampi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05wf30g94","id-type":"ROR","asserted-by":"publisher"}],"name":"Creighton University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Murphy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05byvp690","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas Southwestern Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Golden","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04b6nzv94","id-type":"ROR","asserted-by":"publisher"}],"name":"Brigham and Women's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Schuster","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05wf30g94","id-type":"ROR","asserted-by":"publisher"}],"name":"Creighton University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Conyers","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05wf30g94","id-type":"ROR","asserted-by":"publisher"}],"name":"Creighton University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Sano M, Cummings J, Auer S, et al. Agitation in cognitive disorders: progress in the International Psychogeriatric Association consensus clinical and research definition. Int Psychogeriatr. 2024;36(4):238\u2013250. https:\/\/doi.org\/ 10.1017\/S1041610222001041 DOI: 10.1017\/S1041610222001041","DOI":"10.1017\/S1041610222001041"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. Smoller C, Schiller E, Yamashita K, Silverglate BD, Grossberg GT. Current and emerging pharmacological approaches to agitation in Alzheimer\u2019s disease: a narrative review of new and repurposed therapies. Drugs. 2025;85(11):1391\u20131411. https:\/\/doi.org\/10.1007\/s40265-025-02227-4 DOI: 10.1007\/s40265-025-02227-4","DOI":"10.1007\/s40265-025-02227-4"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Grossberg GT, Sanford A, Montano CB, et al. A US-based practitioner\u2019s guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer\u2019s dementia \u2014 recommendations of an expert, multispecialty advisory panel. Postgrad Med. 2025;137(6):469\u2013485. https:\/\/doi.org\/10.1080\/00325481.2025.2517535 DOI: 10.1080\/00325481.2025.2517535","DOI":"10.1080\/00325481.2025.2517535"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Javaid H, Jha A, Cheema U, et al. Dose-dependent efficacy and safety of brexpiprazole in agitation associated with dementia in Alzheimer\u2019s disease: a systematic review and meta-analysis. Neurol Sci. 2026;47(2):208. https:\/\/ doi.org\/10.1007\/s10072-025-08649-y DOI: 10.1007\/s10072-025-08649-y","DOI":"10.1007\/s10072-025-08649-y"},{"key":"ref4","unstructured":"5. US Food and Drug Administration. FDA approves first non-antipsychotic drug to treat agitation associated with dementia. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-non-antipsychotic-drug-treat-agitation-associated-dementia. Accessed May 27, 2026."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. McCarthy B, Bunn H, Santalucia M, Wilmouth C, Muzyk A, Smith CM. Dextromethorphan-bupropion (Auvelity) for the treatment of major depressive disorder. Clin Psychopharmacol Neurosci. 2023;21(4):609\u2013616. https:\/\/doi.org\/ 10.9758\/cpn.23.1081 DOI: 10.9758\/cpn.23.1081","DOI":"10.9758\/cpn.23.1081"},{"key":"ref6","unstructured":"7. Axosome Therapeutics. Results of the ADVANCE-1 trial. https:\/\/www.axsome.com\/wp-content\/uploads\/2024\/11\/ Axsome_AXS-05-Poster-Presentation_CTAD-2020.pdf. Accessed May 31, 2026."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Cummings J, Grossberg G, Andersson C, et al. Efficacy and safety of AXS-05 in agitation associated with Alzheimer\u2019s disease: results from ACCORD, a phase 3, double-blind, placebo-controlled, relapse prevention trial (PL5.004). Neurology. 2024;102(7 Suppl. 1):5194. https:\/\/doi.org\/10.1212\/WNL-.0000000000205634 DOI: 10.1212\/WNL-.0000000000205634","DOI":"10.1212\/WNL-.0000000000205634"},{"key":"ref8","unstructured":"9. Cummings J, Grossberg G, Streicher C, Tabuteau H. (#184) Efficacy and safety of AXS-05 in Alzheimer\u2019s disease agitation: results from ACCORD-2, a phase 3 randomized withdrawal double-blind placebo-controlled study. https:\/\/www.hmpgloballearningnetwork.com\/node\/371382. Accessed September 29, 2026."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Nair B. Clinical trial designs. Indian Dermatol Online J. 2019;10(2):193\u2013201. https:\/\/doi.org\/10.4103\/idoj.IDOJ_475_18 DOI: 10.4103\/idoj.IDOJ_475_18","DOI":"10.4103\/idoj.IDOJ_475_18"},{"key":"ref10","unstructured":"11. US Food and Drug Administration. FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer\u2019s disease. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease. Accessed June 5, 2026."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Brown EE, Semla T, Reuben DB. Dextromethorphan hydrobromide-bupropion hydrochloride for agitation in dementia: combination or two stand-alone drugs. J Am Geriatr Soc. 2026. https:\/\/doi.org\/10.1111\/jgs.70645 DOI: 10.1111\/jgs.70645","DOI":"10.1111\/jgs.70645"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/10\/dic-2026-6-4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:49:13Z","timestamp":1791283753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/a-review-of-dextromethorphan-and-bupropion-auvelity-for-the-treatment-of-agitation-in-alzheimers-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-6-4","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"dic.2026-6-4"}}